1Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-- perspectiveson current status and future directions: AACR Workshop on cancer stem cells[J]. Cancer Res, 2006,66 (19):9339-9344.
2Moltzahn FR, Volkmer JP, Rottke D, et al. "Cancer stem cells" -Lessons from Hercules to fight the Hydra[J]. Urol Oncol, 2008,26(6) :581-589.
3Kasper S. Stem cells: The root oI prostate cancer? [J]. J Cell Physiol,2008,216(2) :332-336.
4Feldman BJ, Feldman D. The development of androgen-independent prostate cancer[J]. Nat Rev Cancer, 2001,1 (1) :34- 45.
5Kasper S. Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens [J]. Urol Oncol, 2009,27(3) :301-303.
6Collins AT , Berry PA , Hyde C , et al. Prospective identification of tumorigenic prostate cancer stem cells[J ] . Cancer Res ,2005 , 65(23) :10946-10951.
7Salm SN, Burger PE, Coetzee S, et al. Tgf-beta maintains dormancy of prostatic stem cells in the proximal region of ducts[J]. J Cell Biol,2005, 170(1):81-90.
8Foshay K, Miera A, Stuart A,et al. Unraveling the complex nature of prostatecancer stem cells[J]. Cancer Biomark, 2007, 3(4-5): 233-244.
9Reya T, Clevers H. Wnt signaling in stem cells and cancer [J]. Nature, 2005,434(7035) :843-850.
10Mimeault M, Mehta PP, Hauke R, et al. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies[J]. Endocr Rev ,2008,29(2) :234-252.
同被引文献22
1Coon MJ. Cytochrome P450: Nature most versatile biological cata- lyst. Annu Rev Pharmacol Toxicol, 2005, 45 : 1-25.
2Ghotbi R,Christensen M, Roh HK, et ol. Comparisons of CYPIA2 genetic polymorphisms, enzyme activity and the genotype-pheno- type relationship in Swedes and Koreans. Eur J Clin Pharmacol, 2007, 63(6): 537-546.
3Imizumi T, Higaki Y, Hara M, et al. Interaction between cyto- chrome P450 1 A2 genetic potymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis, 2009, 30(10) : 1729-1734.
4Pavanello S, B "chir F, Pulliero A, et al. Interaction between CYP1A2-T2467 DELT polymorphism and smoking in adenoearci- noma and squamous cell carcinoma of the lung. Lung Cancer, 2007, 57(3) : 266-272.
5Olivieri EH, Da-Silva SD, Mendonca FF, et al. CYP1A21C, CYP2E15B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma pa- tients. Oral Oncol, 2009, 45(9) : e73-e79.
6Shimada N, Iwasaki M, Kasuga Y, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazillians and non-Japanese Bra- zilians. J Hum Genet, 2009, 54(4) : 209-215.
7Cunningham JM, Hebbring S J, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic path- ways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prey, 2007, 16(5) : 969-978.
8Finnstr~m N, Bjclfman C, S~terstrfim TG, et al. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT- PCR. Eur J Clin Invest, 2001, 31 (10) : 880-886.
9Martin FL, Patel II, Sozeri O, et al. Constitutive expression of bioactivating enzymes in normal human prostate suggests a capa- bility to activate pro-carcinogens to DNA-dmnaging metabolites. Prostate, 2010, 70(14) : 1586-1599.
10Hrubd E, Trilecovd L, Marvanovd S, et al. Genotoxic polycyclic aromatic hydrocarbons fail to induce the p53-dependent DNA damage response, apoptosis or ceLt-cycle arrest in human prostate carcinoma LNCaP cells. Toxicol Lett, 2010, 197 (3) : 227-235.
